Sangamo Therapeutics, Inc.

DB:GBY Stock Report

Market Cap: €493.9m

Sangamo Therapeutics Past Earnings Performance

Past criteria checks 0/6

Sangamo Therapeutics's earnings have been declining at an average annual rate of -19.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 0.4% per year.

Key information

-19.1%

Earnings growth rate

-9.5%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-0.4%
Return on equity-344.6%
Net Margin-257.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sangamo Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:GBY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2452-135450
30 Jun 2412-248500
31 Mar 2419-328500
31 Dec 23176-258570
30 Sep 23201-250630
30 Jun 23218-199660
31 Mar 23241-127660
31 Dec 22111-192630
30 Sep 22112-178620
30 Jun 22114-172610
31 Mar 22113-176620
31 Dec 21111-178630
30 Sep 21109-181640
30 Jun 21138-135660
31 Mar 21131-124670
31 Dec 20118-121670
30 Sep 20147-76650
30 Jun 20111-102640
31 Mar 20107-96610
31 Dec 19102-95620
30 Sep 1974-118610
30 Jun 1976-104570
31 Mar 1980-90540
31 Dec 1884-68470
30 Sep 1871-63400
30 Jun 1859-62350
31 Mar 1846-58300
31 Dec 1737-55270
30 Sep 1732-51230
30 Jun 1723-58230
31 Mar 1719-72220
31 Dec 1619-72220
30 Sep 1620-76220
30 Jun 1625-66200
31 Mar 1630-52200
31 Dec 1540-41190
30 Sep 1545-31190
30 Jun 1549-29180
31 Mar 1551-24170
31 Dec 1446-26160
30 Sep 1438-30160
30 Jun 1431-29150
31 Mar 1428-27140
31 Dec 1324-27140

Quality Earnings: GBY is currently unprofitable.

Growing Profit Margin: GBY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GBY is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.

Accelerating Growth: Unable to compare GBY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GBY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: GBY has a negative Return on Equity (-344.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangamo Therapeutics, Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gregory HarrisonBofA Global Research
Jonathan AschoffBrean Capital